Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer

NCT02843126 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Breast Cancer

Interventions

DRUG: Trastuzumab
BIOLOGICAL: NK immunotherapy

Sponsor

Fuda Cancer Hospital, Guangzhou

Collaborators

[object Object]